GSK Non-GAAP EPS of £0.55 beats by £0.04, revenue of £8.89B beats by £50M; reaffirms FY outlook
FROM THE WIRE · SEEKINGALPHA.COM
* GSK press release [https://www.gsk.com/media/nw0az1nj/q3-2026-results-announcement.pdf] (GSK [https://seekingalpha.com/symbol/GSK]): Q3 Non-GAAP EPS of £0.55 beats by £0.04. * Revenue of £8.89B (+4.0% Y/Y) beats by £50M. * Specialty Medicines sales £3.9 billion (+15%); HIV…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly results above estimates with 2026 guidance reaffirmed, a favourable factor for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 non-GAAP EPS was £0.55, beating estimates by £0.04.
- 02Revenue rose 4.0% year over year to £8.89B, beating by £50M.
- 03Specialty Medicines sales grew 15% to £3.9 billion.
- 042026 guidance is reaffirmed with turnover growth of 3% to 5%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets